Cover Image
市場調查報告書

流感疫苗的全球市場分析

Global Influenza Vaccine Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 219637
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
流感疫苗的全球市場分析 Global Influenza Vaccine Market Outlook 2022
出版日期: 2016年06月01日 內容資訊: 英文 95 Pages
簡介

本報告提供全球流感疫苗市場相關詳細的分析,疾病及治療方法概要,及主要推動及阻礙市場要素,市場未來預測 (今後7年份),各地區的詳細趨勢,主要企業簡介及開發中產品的資訊彙整,為您概述為以下內容。

第1章 分析師的見解

第2章 調查手法

第3章 流感疫苗:簡介

第4章 產業趨勢與推動因素

  • 大流行病的發生數量增加
  • 可得性的擴大
  • 老年人口的增加
  • 通用流感疫苗的開發
  • 市場內地的產業合作

第5章 產業的相關課題

  • 臨床實驗方面、規定方面的課題
  • 認知度低
  • 醫療基礎設施的不足

第6章 全球流感疫苗市場未來展望

  • 市場現狀與未來展望
  • 主要的已上市疫苗
    • Fluzone/Vaxigrip
    • FluMist
    • Fluarix及Flulaval
    • Anflu
    • Fluvax/Afluria
    • Flucelvax及Fluvirin

第7章 主要地區的市場

  • 南北美洲
  • 歐洲
  • 亞太地區
    • 中國
    • 印度
    • 澳洲
    • 日本
  • 其他的國家 (RoW)

第8章 全球流感疫苗市場:開發平台分析

第9章 全球流感疫苗市場:價格分析

第10章 企業分析

  • Sanofi
    • 營業內容
    • 主要的財務指標
    • 流感疫苗產業
  • GlaxoSmithKline Plc (GSK)
  • 1CSL Ltd.
  • 1AstraZeneca Plc
  • Sinovac Biotech

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global influenza vaccine industry has reported a significant growth in recent years, and is presenting ample opportunities to the industry's players. With increasing pandemic as well as seasonal outbreak and rising awareness, the global influenza vaccine market is poised to scale newer acmes. Moreover, introduction of new vaccines, entry of new players, rising R&D investments, evolving government policies, and infrastructure projects are set to further boost the market's growth.

Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market.

The latest research by RNCOS titled, “Global Influenza Vaccine Market Outlook 2022” unfolds the market dynamics of the influenza vaccine market. The report shows the global influenza vaccine industry being segmented on the basis of major vaccine in the market. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2022. The report also covers advanced stage pipeline analysis of key players, which list down the influenza vaccines already in Phase III trials. The report identifies and highlights the segments that offer maximum opportunity for growth in the global influenza vaccine market.

Our industry analysts studied all the facets of the global influenza vaccine market to portray a crystal clear picture of the current as well as the expected market outlook. Major drivers and trends have been identified that are set to act as catalysts towards boosting the industry's growth, along with roadblocks hindering the market's growth.

The report further highlights the competitive landscape of the global influenza vaccine market, describing the business, financials, and influenza vaccine business of the major industry players. The section is therefore expected to clearly help the reader gain crucial insight into the key market players' performances and strategies for growth. Holistically, the research provides all the pre-requisite information for clients looking to make a debut in this industry, and facilitates them to formulate strategies while going for an investment/partnership in the global influenza vaccine industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Influenza Vaccine - Introduction

4. Industry Trends and Drivers

  • 4.1. Increasing Pandemic Outbreak
  • 4.2. Rising Affordability
  • 4.3. Rising Ageing Population
  • 4.4. Development of Universal Flu Vaccine
  • 4.5. Collaborations in the Market

5. Industry Challenges

  • 5.1. Testing and Regulatory Issues
  • 5.2. Low Awareness
  • 5.3. Lack of Medical and Healthcare Infrastructure

6. Global Influenza Vaccine Market Outlook 2022

  • 6.1. Current Market Overview and Future Outlook
  • 6.2. Major Marketed Vaccines
    • 6.2.1. Fluzone/Vaxigrip
    • 6.2.2. FluMist
    • 6.2.3. Fluarix and Flulaval
    • 6.2.4. Anflu
    • 6.2.5. Fluvax/Afluria
    • 6.2.6. Flucelvax and Fluvirin

7. Key Geographical Market

  • 7.1. Americas
  • 7.2. Europe
  • 7.3. Asia Pacific
    • 7.3.1. China
    • 7.3.2. India
    • 7.3.3. Australia
    • 7.3.4. Japan
  • 7.4. Rest of the World

8. Global Influenza Vaccine Market: Pipeline Analysis

9. Global Influenza Vaccine Market: Pricing Analysis

10. Competitive Assessment

  • 10.1. Sanofi
    • 10.1.1. Business Description
    • 10.1.2. Financial Overview
    • 10.1.3. Influenza Vaccine Business
  • 10.2. GlaxoSmithKline Plc (GSK)
    • 10.2.1. Business Overview
    • 10.2.2. Financial Overview
    • 10.2.3. Influenza Vaccine Business
  • 10.3. CSL Ltd.
    • 10.3.1. Business Overview
    • 10.3.2. Financial Overview
    • 10.3.3. Influenza Vaccine Business
  • 10.4. AstraZeneca Plc
    • 10.4.1. Business Overview
    • 10.4.2. Financial Overview
    • 10.4.3. Influenza Vaccine Business
  • 10.5. Sinovac Biotech
    • 10.5.1. Business Overview
    • 10.5.2. Financial Overview
    • 10.5.3. Influenza Vaccine Business

List of Figures:

  • Figure 6-1: Global - Influenza Vaccine Sales (Million Doses), 2015 & 2022
  • Figure 6-2: Global - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 6-3: Global - Influenza Vaccine Market by Players (%), 2015
  • Figure 6-4: Global - Fluzone/Vaxigrip Sales (Million US$), 2011-2015
  • Figure 6-5: Global - FluMist Sales (Million US$), 2011-2015
  • Figure 6-6: Global - Fluarix and FluLaval Sales (Million US$), 2011-2015
  • Figure 6-7: Global - Anflu Sales (Million Doses), 2011-2015
  • Figure 6-8: Global - Anflu Sales (Million US$), 2011-2015
  • Figure 6-9: Global - Afluria/Fluvax Sales (Million US$), 2013-2015
  • Figure 6-10: Global - Flucevax and Fluvirin Sales (Million US$), 2013-2015
  • Figure 7-1: Global - Influenza Vaccine Market by Region (%), 2015
  • Figure 7-2: US - Influenza Vaccine Sales (Million Doses), 2011-12 to 2015-16
  • Figure 7-3: Americas - Influenza Vaccine Market by Players (%), 2015
  • Figure 7-4: Americas - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 7-5: Europe - Influenza Vaccine Market by Players (%), 2015
  • Figure 7-6: Europe - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 7-7: Europe - Seasonal Influenza Vaccination Coverage in Older Age Group by Country (%), 2011-12 & 2012-13
  • Figure 7-8: Asia-Pacific - Influenza Vaccine Market by Players (%), 2015
  • Figure 7-9: Asia Pacific - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 7-10: Rest of the World - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 8-1: Global - Breakup of Influenza Vaccine Pipeline by Type of Vaccine
  • Figure 10-1: Sanofi - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-2: Sanofi Pasteur - Breakup of Vaccine Segment by Type (%), 2015
  • Figure 10-3: Sanofi Pasteur - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2015
  • Figure 10-4: GlaxoSmithKline Plc - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-5: GlaxoSmithKline Plc - Breakup of Vaccine Segment by Type (%), 2015
  • Figure 10-6: GlaxoSmithKline Plc - Breakup of Total Influenza Vaccine Revenue by Geography (%), 2015
  • Figure 10-7: CSL Ltd - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-8: CSL Ltd - Breakup of bioCSL Revenues by Product Type (%), 2015
  • Figure 10-9: AstraZeneca Plc - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-10: AstraZeneca Plc - Breakup of Infection Segment by Type (%), 2015
  • Figure 10-11: AstraZeneca Plc - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2015
  • Figure 10-12: Sinovac Biotech - Breakup of Vaccine Revenue by Type (%), 2015

List of Tables:

  • Table 7-1: US - Major Influenza Vaccines & Manufacturers (2015-16)
  • Table 7-2: US - Percentage of Children Who Received Influenza Vaccine (2015-16)
  • Table 7-3: US - Percentage of Adults Who Received Influenza Vaccine (2015-16)
  • Table 7-4: US - Number of Pediatric Deaths in Flu Season (2005-06 to 2015-16)
  • Table 7-5: Europe - Major Influenza Vaccines & Manufacturers (2015-16)
  • Table 7-6: China - Vaccine Classification
  • Table 7-7: Australia - Major Influenza Vaccines & Manufacturer (2016)
  • Table 8-1: Global - Influenza Vaccine Pipeline Analysis
  • Table 9-1: Global - Major Influenza Vaccines Cost/Dose (US$), 2016-17
  • Table 10-1: Sanofi - Key Financials (Million US$), 2013-2015
  • Table 10-2: Sanofi - Influenza Vaccines Offered
  • Table 10-3: GlaxoSmithKline Plc - Key Financials (Million US$), 2013-2015
  • Table 10-4: GlaxoSmithKline Plc - Influenza Vaccines Offered
  • Table 10-5: CSL Ltd. - Key Financials (Million US$), 2013-2015
  • Table 10-6: CSL - Influenza Vaccine Portfolio before Merger
  • Table 10-7: CSL - Influenza Vaccine Portfolio after Merger
  • Table 10-8: AstraZeneca Plc - Key Financials (Million US$), 2013-2015
  • Table 10-9: AstraZeneca Plc - Influenza Vaccines Offered
  • Table 10-10: Sinovac Biotech - Key Financials (Million US$), 2013-2015
  • Table 10-11: Sinovac Biotech - Influenza Vaccines Offered
Back to Top